By Josh White
Date: Tuesday 21 May 2024
(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating severe asthma with type 2 inflammation on Tuesday.
The FTSE 100 pharmaceuticals giant said the trials reached their primary endpoints, demonstrating statistically significant and clinically meaningful reductions in asthma exacerbations...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news